PDS Biotechnology Stock Price, News & Analysis (NASDAQ:PDSB) $5.24 -0.04 (-0.76%) (As of 02:46 PM ET) Add Compare Share Share Today's Range$5.19▼$5.3650-Day Range$3.95▼$6.5852-Week Range$3.80▼$13.65Volume227,140 shsAverage Volume607,950 shsMarket Capitalization$163.02 millionP/E RatioN/ADividend YieldN/APrice Target$17.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media PDS Biotechnology MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside237.2% Upside$17.67 Price TargetShort InterestBearish16.88% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.43) to ($1.54) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.49 out of 5 starsMedical Sector872nd out of 949 stocksPharmaceutical Preparations Industry401st out of 427 stocks 3.5 Analyst's Opinion Consensus RatingPDS Biotechnology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $17.67, PDS Biotechnology has a forecasted upside of 237.2% from its current price of $5.24.Amount of Analyst CoveragePDS Biotechnology has only been the subject of 3 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted16.88% of the outstanding shares of PDS Biotechnology have been sold short.Short Interest Ratio / Days to CoverPDS Biotechnology has a short interest ratio ("days to cover") of 11.3, which indicates bearish sentiment.Change versus previous monthShort interest in PDS Biotechnology has recently decreased by 4.89%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldPDS Biotechnology does not currently pay a dividend.Dividend GrowthPDS Biotechnology does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PDSB. Previous Next 1.9 News and Social Media Coverage News SentimentPDS Biotechnology has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.Search Interest16 people have searched for PDSB on MarketBeat in the last 30 days. This is an increase of 45% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added PDS Biotechnology to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, PDS Biotechnology insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 10.00% of the stock of PDS Biotechnology is held by insiders.Percentage Held by InstitutionsOnly 25.78% of the stock of PDS Biotechnology is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for PDS Biotechnology are expected to decrease in the coming year, from ($1.43) to ($1.54) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of PDS Biotechnology is -3.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of PDS Biotechnology is -3.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPDS Biotechnology has a P/B Ratio of 3.38. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About PDS Biotechnology Stock (NASDAQ:PDSB)PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. The company is developing various product candidates, which are in preclinical trials, including PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for treating prostate and breast cancers; PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers; and PDS0104, which include Tyrosinase-related protein 2 for the treatment of melanoma. In addition, it is developing PDS0201 for treating tuberculosis; PDS0202, an influenza vaccine candidate; and PDS0203, a vaccine for the prevention of COVID-19. The company has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Florham Park, New Jersey.Read More PDSB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PDSB Stock News HeadlinesNovember 28, 2023 | marketwatch.comPDS Biotechnology CFO Matthew Hill to Exit; Lars Boesgaard Named as ReplacementNovember 28, 2023 | markets.businessinsider.comPDS Biotechnology Appoints Lars Boesgaard To Succeed Matthew Hill As CFODecember 5, 2023 | Autonomix (Ad)How to Invest Early In the Next Potential Breakthrough Nerve-Sensing TechnologyAutonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 28, 2023 | finance.yahoo.comPDS Biotech Appoints Lars Boesgaard as Chief Financial OfficerNovember 17, 2023 | markets.businessinsider.comPositive Outlook for PDS Biotechnology: Strong Q3 Financials, Promising Development Pipeline, and Strategic AdvancementsNovember 15, 2023 | finance.yahoo.comPDS Biotechnology Corporation (NASDAQ:PDSB) Q3 2023 Earnings Call TranscriptNovember 14, 2023 | marketwatch.comPDS Biotechnology Shares Rise 20% After Narrower-Than-Expected 3Q LossNovember 14, 2023 | finanznachrichten.dePDS Biotechnology Corporation: PDS Biotech Reports Third Quarter 2023 Financial Results and Provides Business UpdateDecember 5, 2023 | Autonomix (Ad)How to Invest Early In the Next Potential Breakthrough Nerve-Sensing TechnologyAutonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 14, 2023 | finance.yahoo.comPDS Biotechnology Corp (PDSB) Reports Increased Net Loss in Q3 2023 Amid Advancements in ...November 14, 2023 | benzinga.comPDS Biotechnology: Q3 Earnings InsightsNovember 14, 2023 | finance.yahoo.comPDS Biotech Reports Third Quarter 2023 Financial Results and Provides Business UpdateNovember 13, 2023 | benzinga.comA Preview Of PDS Biotechnology's EarningsNovember 10, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: PDS Biotechnology (PDSB) and Shattuck Labs (STTK)November 9, 2023 | msn.comPDS Biotech reports encouraging survival data for HPV 16+ cancer therapyNovember 9, 2023 | finance.yahoo.comPDS Biotech Announces Updated Survival Data from NCI-Led Phase 2 Clinical Trial of PDS0101-Based Triple Combination Therapy in Advanced HPV16-Positive Cancer Patients which Show 75% Survival of ICI Naïve Patients at 36 MonthsNovember 7, 2023 | finance.yahoo.comPDS Biotechnology Announces Conference Call and Webcast for Third Quarter 2023 Financial ResultsOctober 28, 2023 | seekingalpha.comPDSB PDS Biotechnology CorporationOctober 24, 2023 | markets.businessinsider.comPromising Potential of PDS Biotechnology’s PDS0101 in HPV16-Positive HNSCC Treatment: An Analysis of the VERSATILE-002 Phase 2 Study ResultsOctober 23, 2023 | finance.yahoo.comPDS Biotech Announces Preliminary Biomarker Study Results in Subset of Advanced HPV-Positive Head and Neck Cancer Patients at ESMOOctober 11, 2023 | markets.businessinsider.comThe Latest Analyst Ratings for PDS BiotechnologyOctober 11, 2023 | finance.yahoo.comPDS Biotech Announces Interim Safety and Immune Response Data from Phase 1/2 Clinical Trial Evaluating Novel Antibody Drug Conjugate PDS0301 Combined with Docetaxel to Treat Metastatic Prostate CancerOctober 6, 2023 | markets.businessinsider.comPromising Clinical Trial Results and Undervalued Potential Bolster Buy Rating for PDS Biotechnology: An AnalysisOctober 3, 2023 | finance.yahoo.comPDS Biotech Announces Interim 24-Month Survival Rate of 74% in Immune Checkpoint Inhibitor Naïve Head and Neck Cancer Patients Treated with PDS0101 in Combination with KEYTRUDA® (pembrolizumab)October 2, 2023 | finance.yahoo.comPDS Biotech Announces PDS0101 Combined with Chemoradiotherapy Associated with Rapid Decline in Circulating Tumor DNA (ctDNA/cfDNA)September 26, 2023 | finance.yahoo.comPDS Biotech to Present at the LD Micro Main Event XVISeptember 25, 2023 | finance.yahoo.comPDS Biotech Reschedules Key Opinion Leader Roundtable Addressing Current and Future Treatments for Recurrent/Metastatic HPV-Positive HNSCC and the Potential Application of PDS0101See More Headlines Receive PDSB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PDS Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/10/2021Today12/05/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/26/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PDSB CUSIPN/A CIK1472091 Webwww.pdsbiotech.com Phone(800) 208-3343Fax908-790-1212Employees26Year FoundedN/APrice Target and Rating Average Stock Price Target$17.67 High Stock Price Target$21.00 Low Stock Price Target$12.00 Potential Upside/Downside+237.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.71) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-40,850,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-144.24% Return on Assets-76.85% Debt Debt-to-Equity Ratio0.96 Current Ratio6.21 Quick Ratio6.21 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.55 per share Price / Book3.38Miscellaneous Outstanding Shares31,110,000Free Float27,997,000Market Cap$163.02 million OptionableNot Optionable Beta2.01 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesDr. Frank K. Bedu-Addo Ph.D. (Age 58)President, CEO & Director Comp: $854.1kMr. Matthew C. Hill CPA (Age 54)CFO, Principal Financial & Accounting Officer Comp: $504.09kMs. Lauren V. Wood M.D. (Age 63)Chief Medical Officer Comp: $568.5kDr. Joe J. DervanVP of Research & DevelopmentDr. Gregory L. Conn Ph.D. (Age 68)Chief Scientific Officer Comp: $220.46kMs. Deanne RandolphVP of Commercial Development & Head of Investor RelationsMr. Spencer Brown J.D. (Age 53)Senior VP & General Counsel Ms. Nathalie RiebelSenior Vice President of Clinical OperationsMr. Sanjay ZaveriSenior Vice President of Business DevelopmentMs. Janetta Trochimiuk (Age 60)Controller More ExecutivesKey CompetitorsAstria TherapeuticsNASDAQ:ATXSSelecta BiosciencesNASDAQ:RNACTheseus PharmaceuticalsNASDAQ:THRXAltimmuneNASDAQ:ALTImmutepNASDAQ:IMMPView All CompetitorsInstitutional OwnershipDeutsche Bank AGBought 15,094 shares on 11/24/2023Ownership: 0.055%EP Wealth Advisors LLCBought 10,207 shares on 11/24/2023Ownership: 0.033%AQR Capital Management LLCBought 22,427 shares on 11/15/2023Ownership: 0.073%Mercer Global Advisors Inc. ADVSold 12,500 shares on 11/15/2023Ownership: 0.040%California State Teachers Retirement SystemSold 3,131 shares on 11/14/2023Ownership: 0.020%View All Institutional Transactions PDSB Stock Analysis - Frequently Asked Questions Should I buy or sell PDS Biotechnology stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for PDS Biotechnology in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PDSB shares. View PDSB analyst ratings or view top-rated stocks. What is PDS Biotechnology's stock price target for 2024? 3 equities research analysts have issued 12-month price targets for PDS Biotechnology's shares. Their PDSB share price targets range from $12.00 to $21.00. On average, they anticipate the company's share price to reach $17.67 in the next twelve months. This suggests a possible upside of 237.2% from the stock's current price. View analysts price targets for PDSB or view top-rated stocks among Wall Street analysts. How have PDSB shares performed in 2023? PDS Biotechnology's stock was trading at $13.20 at the beginning of 2023. Since then, PDSB shares have decreased by 60.3% and is now trading at $5.24. View the best growth stocks for 2023 here. When is PDS Biotechnology's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 26th 2024. View our PDSB earnings forecast. How were PDS Biotechnology's earnings last quarter? PDS Biotechnology Co. (NASDAQ:PDSB) posted its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.22) by $0.02. During the same quarter last year, the firm posted ($0.23) earnings per share. What other stocks do shareholders of PDS Biotechnology own? Based on aggregate information from My MarketBeat watchlists, some companies that other PDS Biotechnology investors own include Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), Advanced Micro Devices (AMD), Boxlight (BOXL), Otonomy (OTIC), Bionano Genomics (BNGO), CymaBay Therapeutics (CBAY), Cerecor (CERC), Enterprise Products Partners (EPD) and Evofem Biosciences (EVFM). Who are PDS Biotechnology's major shareholders? PDS Biotechnology's stock is owned by a variety of institutional and retail investors. Top institutional investors include Northern Trust Corp (0.80%), LPL Financial LLC (0.76%), Commonwealth Equity Services LLC (0.22%), Vontobel Holding Ltd. (0.13%), Simplex Trading LLC (0.00%) and Trexquant Investment LP (0.08%). Insiders that own company stock include Delyle W Bloomquist, Matthew C Hill, Steve C Glover and Voorhees Seth Van. View institutional ownership trends. How do I buy shares of PDS Biotechnology? Shares of PDSB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:PDSB) was last updated on 12/5/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PDS Biotechnology Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.